Ovarian function comprises two primary components that are biologically inseparable. The first is the gametogenic and reproductive function: preservation of the follicular reserve, follicular growth and selection, oocyte maturation, ovulation and formation of the corpus luteum. The second is the endocrine function: cyclic production of estrogens, progesterone, androgens, inhibins, activins and anti-Müllerian hormone. Ovarian hormones coordinate the reproductive cycle, prepare the endometrium and genital tract for fertilization and implantation and, at the same time, exert systemic effects on the brain, liver, skeletal muscle, adipose tissue, pancreas, bone, endothelium and cardiovascular system.
Reproductive capacity does not, however, depend on the ovary in isolation. It requires a functioning hypothalamic-pituitary-ovarian axis, ovulation, tubal patency, interaction between gametes, oocyte and sperm competence, embryonic development and endometrial receptivity. The ovary provides the oocyte and the endocrine support for the cycle, but fertilization and implantation involve the entire reproductive system. A regular menstrual period therefore frequently suggests normal ovulatory activity, but does not by itself demonstrate fertility, just as an AMH value does not directly measure oocyte quality or the probability of spontaneous conception.
Extraprodutive effects are not marginal functions. Estrogens, progesterone and androgens help modulate appetite, nutrient utilization, insulin sensitivity, muscle mass, body fat distribution, temperature, sleep, bone health and psychophysical well-being. The thyroid and adrenal glands act on the same organs through different mechanisms. Thyroid hormones regulate metabolic activity, heat production, oxygen consumption and carbohydrate and lipid turnover; cortisol, by contrast, enables adaptation to fasting, exercise, infections and stressful stimuli by making the required energy substrates available. The ovary, thyroid and adrenal glands remain distinct glands, but their effects converge on the systems controlling reproduction, energy and body composition.
The connection is bidirectional. Ovarian hormones influence metabolism, while metabolic status in turn affects reproductive function. Insulin resistance can promote excessive ovarian androgen production and impair follicular maturation; insufficient energy availability can reduce GnRH pulsatility and interrupt ovulation; increased visceral fat can alter adipokines, inflammation and sex steroid bioavailability. The menstrual cycle can therefore be affected by nutritional and metabolic changes, but it represents only the most visible manifestation of a broader systemic relationship.
The same interdependence becomes particularly evident during perimenopause. The number of available follicles declines, ovulation becomes less predictable and estradiol and progesterone production fluctuates before decreasing permanently. At the same time, sleep may be fragmented by hot flushes, muscle mass tends to decline and adipose tissue is more readily redistributed towards the abdomen. These changes overlap with the effects of age, physical activity, diet, working conditions and any coexisting thyroid or metabolic diseases.
Fatigue, weight gain, difficulty concentrating, insomnia, palpitations, irritability, menstrual changes and reduced recovery capacity are real symptoms, but they do not automatically identify the system involved. They may result from the menopausal transition, thyroid dysfunction, glycemic abnormalities, obstructive sleep apnea, anemia, medications, psychological stress, energy deficiency or combinations of several factors. The similarity of the manifestations makes it necessary to reconstruct the clinical picture before attributing it to a single hormone.
Hormones, moreover, do not need to maintain constant concentrations. Estradiol and progesterone change during the ovarian cycle; FSH and inhibins vary with follicular growth and declining reserve; cortisol follows a circadian rhythm; TSH varies according to time of day, age, pregnancy and acute illness; insulin increases after meals. Variability is a physiological property of endocrine systems and does not in itself represent a loss of balance.
For this reason, the expression “hormonal imbalance” may generically describe a group of symptoms, but it does not correspond to a single medical diagnosis. There is no single panel capable of simultaneously measuring fertility, ovarian health, thyroid function, adrenal activity and metabolism. Each test becomes meaningful only when selected to answer a precise clinical question and interpreted at the correct physiological time.
The relevance of these interactions is considerable. Polycystic ovary syndrome affects approximately 10 to 13% of women of reproductive age, depending on the criteria used, and is frequently associated with ovulatory dysfunction, hyperandrogenism, insulin resistance and metabolic risk. Thyroid diseases are markedly more common in women, while the increasing postmenopausal population makes it increasingly important to distinguish the effects of follicular and estrogen loss from those of aging and concomitant metabolic conditions.
The ovary is simultaneously a reproductive organ and a dynamic endocrine gland. Its functional unit is the follicle, which consists of the oocyte and the somatic cells that support it. The endocrine physiology of the ovary therefore integrates gamete development, hormone production and communication with the hypothalamus, pituitary gland, uterus and peripheral tissues. Growth of the dominant follicle, ovulation and formation of the corpus luteum are consecutive phases of the same process.
The ovarian reserve is established before birth. Oogonia enter meiosis during fetal life and become primary oocytes arrested in prophase of the first meiotic division, enclosed within primordial follicles. No new clinically significant reserve is formed after birth: the follicular pool decreases over time through atresia and, to a much lesser extent, through ovulation. The duration of reproductive life therefore depends on the initial number of follicles, the rate at which they are lost and the biological age of the oocytes.
Folliculogenesis begins with activation of primordial follicles, continues through the primary and secondary stages and leads to formation of antral follicles. The initial phases depend mainly on intraovarian signals; when the antrum develops, FSH and LH assume an increasing role. Most follicles that begin growing undergo atresia. Under physiological conditions, generally only one acquires dominance and reaches ovulation during the same cycle.
The two-cell, two-gonadotropin model operates within the antral follicle. LH stimulates theca cells to produce androgens; FSH induces aromatase in granulosa cells, which converts androgens into estradiol. Granulosa cells also produce inhibin B and other signals that modulate pituitary secretion. The initial rise in FSH recruits a follicular cohort, while the subsequent increase in estradiol and inhibin B reduces FSH and favors the most sensitive follicle, which becomes dominant.
During the follicular phase, estradiol predominantly exerts negative feedback. When the dominant follicle reaches maturity, high and sustained estradiol concentrations temporarily convert feedback to positive and trigger the LH surge. The sequence leading to ovulation includes resumption of oocyte meiosis, expansion of the cumulus, enzymatic changes in the follicular wall and rupture of the follicle. The secondary oocyte is thereby released and can be captured by the fallopian tube.
Ovulation is not equivalent to menstruation and does not by itself guarantee conception. After tubal capture, the oocyte remains fertilizable for a limited period; spermatozoa must pass through the cervix, uterine cavity and fallopian tube, complete capacitation and reach the gamete. Fertilization usually occurs within the tubal ampulla. The zygote begins cell division while moving towards the uterus, but implantation also depends on embryo quality and endometrial receptivity.
After ovulation, the luteinized follicular cells form the corpus luteum, which mainly produces progesterone, but also estradiol and inhibin A. Progesterone transforms the proliferative endometrium into a secretory endometrium, reduces myometrial excitability and alters cervical mucus. If implantation occurs, human chorionic gonadotropin initially maintains the corpus luteum and progesterone production; the placenta subsequently assumes steroidogenic function progressively. If pregnancy does not occur, luteolysis causes progesterone and estradiol concentrations to fall and triggers menstruation.
The ovarian cycle and uterine cycle are coordinated, but they are not synonymous. The former comprises follicular growth, ovulation and the luteal phase; the latter comprises menstruation, proliferation and secretory transformation of the endometrium. Bleeding can occur even in the absence of ovulation, while amenorrhea and oligomenorrhea may reflect hypothalamic suppression, ovarian insufficiency, hyperprolactinemia, thyroid dysfunction, PCOS or other conditions. Cycle regularity is therefore a useful clinical indicator, not a complete measure of reproductive capacity.
Ovarian reserve mainly describes the quantity of follicles that can still be recruited, not the chromosomal quality of the oocytes. Age, antral follicle count and AMH help estimate the expected response to ovarian stimulation, but cannot precisely determine whether a woman will conceive spontaneously. Oocyte quality and the risk of aneuploidy depend mainly on age. Fertility and the probability of live birth also depend on tubal, uterine, male, genetic and general factors.
Reproductive and endocrine functions are therefore integrated. The follicle that enables oocyte maturation also produces estradiol; the corpus luteum that supports the endometrium simultaneously exposes the entire body to progesterone; the progressive loss of follicles first alters ovulatory regularity and subsequently the metabolic, skeletal and cardiovascular environment. Systemic effects do not replace the primary reproductive function, but arise from the same biological apparatus.
Estrogens, particularly estradiol, bind to receptors located in the central nervous system, adipose tissue, skeletal muscle, liver, pancreas, endothelium and bone. Their action modifies the expression of numerous genes and activates rapid intracellular signals, influencing how the body obtains, uses and stores energy. Reduced estrogen exposure therefore causes not only reproductive alterations and gynecological symptoms, but also changes the context in which appetite, muscle mass, lipids and glucose are regulated.
In the brain, ovarian estrogens interact with hypothalamic circuits that process hunger and satiety signals. Leptin, insulin and gastrointestinal hormones communicate the presence of energy reserves and the arrival of nutrients; estradiol modulates neuronal responses to these signals. Appetite nevertheless remains the result of integration between biology, food availability, habits, sleep, emotions and the social environment.
In skeletal muscle, estradiol contributes to the utilization of glucose and fatty acids and supports mitochondrial function. Muscle is one of the main tissues responsible for glucose uptake after meals and is an important component of energy expenditure. Preservation of muscle mass therefore helps maintain insulin sensitivity and limits the progressive metabolic slowing associated with age and inactivity.
In the liver, estrogens modulate glucose production, lipoprotein synthesis and clearance and triglyceride accumulation. In adipose tissue, they influence adipocyte formation, lipolysis, the inflammatory response and the site at which fat is deposited. These effects explain why changes in ovarian function can modify body composition even without an immediate change in weight.
During much of adult life, fat tends to be distributed predominantly within the gluteofemoral subcutaneous compartments. As estrogen exposure declines, the tendency to accumulate adipose tissue within the abdomen and around the internal organs increases. This redistribution is clinically important because visceral adipose tissue is more closely associated with insulin resistance, inflammation, dyslipidemia and cardiovascular risk than peripheral subcutaneous fat.
A woman may therefore maintain an apparently stable weight while muscle mass decreases and fat mass increases. Scales record only total mass and do not distinguish between different compartments; waist circumference, muscle strength, activity level and changes over time may therefore provide more useful information than a single weight measurement.
Progesterone contributes to systemic regulation mainly during the phase following ovulation. It produces a slight increase in body temperature, modulates ventilation and is converted into neuroactive metabolites capable of interacting with GABA receptors. These effects may influence sleep, mood, appetite and perception of fatigue without necessarily indicating a pathological condition.
Cyclic changes in ovarian hormones may temporarily modify fluid retention and weight. An increase observed in the days before menstruation may be due to water, intestinal contents and changes in food intake and does not automatically correspond to an increase in fat mass. This distinction is important because short-term physiological fluctuations do not require drastic diets or hormonal interventions.
Ovarian androgens contribute to estrogen synthesis, muscle function, bone health and sexuality. Their action depends on ovarian and adrenal production, but also on the amount bound to sex hormone-binding globulin. Only a small proportion of testosterone circulates freely or is weakly bound and can immediately reach target tissues.
SHBG is produced by the liver and represents an important link between metabolism and sex hormones. Insulin and visceral adiposity tend to reduce its synthesis; oral estrogens and thyroid hormones can instead increase it. Reduced SHBG makes a larger proportion of testosterone available and can amplify acne, hirsutism and alopecia even when total testosterone is not markedly elevated.
Insulin enables muscle and adipose tissue to use glucose and limits hepatic production when energy is already available. If tissues become less sensitive, the pancreas compensates by secreting larger amounts of insulin. During this phase, blood glucose may remain normal while hyperinsulinemia exerts progressive effects on the liver, adipose tissue and ovary.
Ovarian androgen-producing cells remain sensitive to insulin even when muscle and liver respond less effectively. Hyperinsulinemia can therefore enhance LH action, increase androgen steroidogenesis and simultaneously reduce hepatic SHBG production. Increased biologically available androgens impair normal follicular maturation and promote menstrual irregularities.
This circuit is central to polycystic ovary syndrome. The syndrome simultaneously comprises reproductive, metabolic and psychological components. PCOS results from the interaction between genetic predisposition, altered neuroendocrine regulation, androgen production and metabolic factors. Hyperandrogenism, ovulatory dysfunction or metabolic risk may predominate in different patients, and there is no single presentation that applies to all women.
Visceral adiposity, when present, amplifies insulin resistance and hyperinsulinemia, which in turn increase androgen production. Androgens may further promote abdominal fat deposition and make regular ovarian function more difficult. This creates a metabolic-ovarian circuit in which metabolism and ovarian function influence each other.
PCOS should not, however, be considered a simple consequence of obesity. It can also occur in women of normal weight, in whom insulin resistance may be less evident but still present. Similarly, obesity and irregular cycles are not sufficient to establish the diagnosis, because numerous thyroid, pituitary, adrenal or nutritional conditions can produce similar manifestations.
Adipose tissue also participates in endocrine regulation through leptin, adiponectin and cytokines. Leptin informs the brain about the amount of stored energy; adiponectin promotes insulin sensitivity; cytokines produced by visceral fat can sustain a chronic low-grade inflammatory state. The composition and distribution of adipose tissue therefore influence metabolism more than its mere presence.
Energy availability represents the opposite side of the problem. It corresponds to the energy remaining for physiological functions after subtracting the cost of physical activity. When dietary intake does not compensate for expenditure, the hypothalamus receives signals of insufficiency through reductions in leptin, insulin and IGF-1 and through changes in ghrelin and peripheral thyroid hormones.
The response consists of restricting functions that require substantial energy. Activity of the hypothalamic-pituitary-ovarian axis decreases, estrogen production declines and the cycle may become irregular or cease. Female hypogonadotropic hypogonadism may therefore develop following dietary restriction, weight loss, excessive exercise or stress, even in women who maintain an apparently normal body mass index. Recognition and correction of energy deficiency, excessive exercise and any contributing psychological factors are essential for recovery of the axis.
In this context, menstrual disruption is the visible sign of an adaptation that also involves bone, metabolism and cardiovascular function. Reduced estrogen exposure limits bone formation, while energy deficiency reduces the availability of nutrients and anabolic signals. Correction does not consist of artificially inducing bleeding, but of restoring energy availability compatible with the body’s needs.
Anti-Müllerian hormone provides different information. It is produced by small ovarian follicles and primarily reflects the growing follicular population. It does not measure metabolic rate, does not indicate how “balanced” the hormones are and, by itself, does not permit assessment of oocyte quality, ovulation or the probability of spontaneous conception.
Weight and body composition therefore emerge from the interaction between hormones, diet, physical activity, muscle mass, sleep, medications, genetic predisposition and the environment. Hormones can make this context more or less favorable, but they are rarely its sole determinant. An appropriate assessment must recognize their biological role without turning it into a complete and automatic explanation.
The thyroid mainly produces thyroxine, or T4, and a smaller amount of triiodothyronine, or T3. Secretion is regulated by pituitary TSH, which increases when available thyroid hormones are insufficient and decreases when they are excessive. Most biologically active T3 derives from conversion of T4 within peripheral tissues, where specific deiodinases allow each organ to modulate the local intensity of the signal.
T3 enters the cell nucleus and modifies the expression of genes involved in mitochondrial function, heat production and glucose and lipid metabolism. Thyroid hormones also influence heart rate, intestinal motility, bone turnover and the ability of muscle to use energy. Sufficiently significant dysfunction therefore produces systemic symptoms that may also involve weight, strength and psychophysical well-being.
The ovary and thyroid do not form a single axis, but communicate through the hypothalamus, pituitary gland, liver and peripheral tissues. Thyroid hormones alter production of the proteins that transport sex steroids, hepatic metabolism of estrogens and androgens and prolactin secretion. Estrogens, in turn, influence the proteins that carry thyroid hormones in the blood.
In primary hypothyroidism, the thyroid produces insufficient amounts of T4 and T3 and the pituitary increases TSH in an attempt to stimulate it. Reduced thyroid activity slows thermogenesis, alters lipid metabolism and promotes water and sodium retention. Fatigue, cold intolerance, constipation, dry skin, slowing and weight gain may occur.
Weight gain attributable to hypothyroidism alone is generally modest and includes a substantial component of fluid retention. Severe obesity or a rapid increase in fat mass can rarely be explained exclusively by reduced thyroid hormone production. Treatment removes the effects of hormone deficiency, but does not eliminate the influence of diet, physical activity, sleep and body composition.
Hypothyroidism can affect the ovary through prolactin. In more marked forms, increased hypothalamic TRH stimulates not only TSH, but also prolactin secretion. If prolactin remains elevated, it reduces GnRH pulsatility and gonadotropin secretion, promoting menstrual abnormalities and reduced estrogen production.
Dysfunction also alters hepatic SHBG synthesis and sex steroid metabolism. The free fractions of androgens and estrogens may therefore change even without proportional changes in total concentrations. The clinical result is not identical in all women: longer cycles, amenorrhea or heavier and prolonged bleeding may occur.
When hypothyroidism is the primary cause, restoration of euthyroidism tends to normalize prolactin, metabolism and ovarian function. If fatigue, weight gain or menstrual irregularities persist despite appropriate TSH and FT4 values, different explanations must be considered instead of inappropriately increasing the levothyroxine dose.
In hyperthyroidism, excessive thyroid hormone action accelerates thermogenesis, heart rate and energy substrate consumption. Palpitations, tremor, sweating, insomnia, heat intolerance, weakness and weight loss may occur. Weight loss often also involves muscle mass and does not represent a favorable improvement in body composition.
Increased muscle catabolism reduces strength and functional capacity. Increased hepatic glucose production and lipolysis may also worsen glycemic control in predisposed individuals. Hyperthyroidism is therefore not a model of efficient metabolism, but a catabolic condition capable of damaging muscle, bone and the cardiovascular system.
Thyroid hormones increase hepatic SHBG production. Total sex steroid concentrations may rise while the free fraction changes differently. Some women develop less frequent or lighter cycles, but these manifestations are more common in overt and severe disease than in mild biochemical abnormalities.
Estrogens, in turn, alter interpretation of thyroid function by increasing hepatic synthesis of thyroxine-binding globulin, or TBG. When TBG increases, a larger amount of T4 and T3 remains bound to protein; the body compensates by increasing total hormone concentrations while generally maintaining a stable free fraction.
The effect is particularly evident with oral estrogens, which reach the liver directly through the portal circulation. In women with a normally functioning thyroid, adaptation occurs spontaneously. In women treated with levothyroxine, however, the increase in TBG may temporarily reduce hormone availability and increase TSH.
Oral estrogen therapy may therefore require TSH monitoring and, in some patients, adjustment of levothyroxine. Transdermal estradiol largely avoids first-pass hepatic metabolism and produces smaller effects on TBG and SHBG. This difference is considered when selecting therapy, together with thromboembolic risk, symptoms and individual preferences.
Autoimmune thyroid diseases are more common in women and may coexist with other autoimmune disorders. In primary ovarian insufficiency, it is important to assess the possible association with thyroid autoimmunity and, in selected contexts, adrenal autoimmunity.
The presence of antithyroid antibodies does not, however, demonstrate that nonspecific symptoms are caused by the thyroid. Antibodies indicate an autoimmune predisposition and increase the probability of developing dysfunction over time, but a woman may remain euthyroid for many years. Actual thyroid function must be established using TSH and FT4.
A higher prevalence of thyroid autoimmunity has also been observed in some populations with PCOS. The association does not demonstrate that one condition directly causes the other, because both are common and may share genetic, immunological and metabolic factors. Each disorder must be evaluated according to its own diagnostic criteria.
Clinical overlap becomes particularly important during perimenopause. Palpitations, sweating, insomnia and irritability may occur both during hot flushes and in hyperthyroidism; fatigue, weight gain, cognitive difficulties and mood changes may occur both in hypothyroidism and during the menopausal transition.
The pattern of symptom onset can help distinguish them. Hot flushes are sudden episodes of heat, vasodilation and sweating; hyperthyroidism more commonly produces persistent heat intolerance accompanied by tachycardia, tremor and weight loss. Hypothyroidism instead tends to be associated with cold intolerance, constipation and dry skin, manifestations that are not typical of menopause alone.
Symptoms are nevertheless insufficiently specific to replace testing. TSH generally represents the first investigation for assessing thyroid function. If elevated, FT4 distinguishes overt from subclinical hypothyroidism; if suppressed, FT4 and FT3 allow assessment of thyrotoxicosis.
Thyroid ultrasound answers a different question. It describes thyroid size, structure and nodules, but does not measure the amount of hormone produced. It should not be routinely requested for fatigue, weight gain or menstrual abnormalities in the absence of goiter, palpable nodules or other cervical findings.
Levothyroxine should be used to correct a documented deficiency. Administering it to a euthyroid woman to accelerate metabolism may cause tachycardia, atrial fibrillation, insomnia, bone loss and muscle catabolism. Supplements containing excessive iodine or thyroid extracts can also alter glandular function and interfere with treatment.
The correct relationship between the ovary and thyroid therefore does not consist of attempting to keep both axes at arbitrarily “optimal” values, but of recognizing when a variation is physiological, when it depends on estrogen therapy and when it represents true thyroid disease. Only the latter requires specific thyroid treatment.
Cortisol is produced by the adrenal cortex under the control of the hypothalamic-pituitary-adrenal axis. The hypothalamus releases CRH and vasopressin, which stimulate the pituitary gland to produce ACTH; ACTH reaches the adrenal gland and induces glucocorticoid synthesis. When the stimulus decreases, cortisol exerts negative feedback and limits its own further production.
Secretion follows a circadian rhythm. Concentrations begin to rise before waking, generally reach their highest levels in the morning and progressively decline during the day. Shorter pulses are superimposed on this pattern, allowing tissues to receive a variable and adaptable signal.
The rhythm depends mainly on the sleep-wake cycle and may change during night work, jet lag, insomnia and acute illness. A value measured without considering the time and collection conditions may therefore be difficult to interpret. Cortisol should not be regarded as a substance that is constantly high or low, but as a hormone whose usefulness depends on its ability to vary at the appropriate time.
During fasting, exercise, infection or trauma, cortisol makes glucose, amino acids and fatty acids available. It increases hepatic glucose production, promotes substrate mobilization and supports the arterial pressure response to catecholamines. It also modulates inflammation and prevents the immune response from becoming excessive.
A transient increase during a demanding stimulus is therefore physiological. The objective is not to keep cortisol at the lowest possible value at all times, but to produce an adequate response and terminate it when it is no longer required. The portrayal of cortisol as an exclusively harmful hormone does not correspond to its biological function.
Psychological stress can influence energy and weight through several pathways. Activation of the HPA axis temporarily alters substrate availability; insomnia reduces recovery; fatigue limits spontaneous activity; emotions may modify appetite and food choices. Some individuals eat more, others reduce intake and still others alternate restriction with uncontrolled eating.
Metabolic effects therefore do not depend on a single mechanism. Sleep, eating behavior, physical activity, mood and social context may mediate an important part of the relationship between stress and weight. Attributing every increase in abdominal circumference to persistently high cortisol excessively simplifies a heterogeneous process.
Sleep deprivation can reduce insulin sensitivity, increase hunger and alter neuroendocrine regulation of appetite. During perimenopause, hot flushes and night sweats may fragment sleep and create a sequence in which fatigue, reduced physical activity and greater difficulty controlling food intake worsen metabolic risk.
The stress axis also communicates with the hypothalamic-pituitary-ovarian axis. CRH, glucocorticoids and sympathetic signals can reduce the activity of neurons regulating kisspeptin and GnRH, modify the pituitary response and directly influence ovarian cells. The effect varies according to intensity, duration and concurrent energy availability.
Acute stress can temporarily delay ovulation or alter the duration of a cycle. When the stimulus persists together with dietary restriction, weight loss or excessive exercise, hypothalamic suppression may become stable. Reduced ovarian activity in this context represents an adaptive response to an environment perceived as unfavorable.
Functional hypothalamic amenorrhea is not, however, caused exclusively by cortisol. Reduced leptin, insulin and IGF-1, increased ghrelin, changes in peripheral thyroid hormones and activation of the HPA axis converge on the hypothalamus. The system integrates nutritional, metabolic and psychological signals rather than responding to a single hormone.
A woman may develop this disorder even at a normal weight. It is sufficient for energy intake to be inadequate in relation to training and other physiological requirements. Correction therefore requires restoration of energy availability, not a generic treatment intended to lower cortisol.
Physical exercise physiologically increases ACTH and cortisol when intensity and duration are sufficient. The response helps maintain blood glucose during activity and makes fatty acids available. In an adequately nourished and trained person, the increase is followed by recovery and contributes to adaptation.
The problem arises when the load consistently exceeds recovery capacity and diet does not compensate for expenditure. Performance, bone mass and ovarian activity may decline. It is therefore unnecessary to avoid all exercise that increases cortisol, but intensity, volume, nutrition and rest should be adapted to individual characteristics.
“Low cortisol” programs often confuse the physiological acute increase with pathological hypercortisolism. Walking, breathing exercises and light activities may be useful for untrained people or those experiencing severe stress, but resistance training and aerobic exercise remain essential tools for muscle, bone and metabolic health when appropriately planned.
There is no universal cortisol excess in PCOS. Some women show changes in the stress response, peripheral glucocorticoid metabolism or adrenal androgen production, but these findings do not represent the sole cause of the syndrome. PCOS and hypercortisolism can produce similar manifestations, but require different diagnoses.
Cushing’s syndrome is caused by pathological and persistent exposure to glucocorticoids. The most common cause is prolonged corticosteroid use for other diseases; endogenous forms result from excessive pituitary or ectopic ACTH production or from an adrenal lesion that autonomously produces cortisol.
In this condition, cortisol increases hepatic glucose production, antagonizes insulin and promotes diabetes and visceral fat accumulation. At the same time, it stimulates muscle protein breakdown, reduces bone formation and thins the skin. This results in proximal weakness, relatively thin limbs, central adiposity, osteoporosis, purple striae and easy bruising.
Cushing’s syndrome can also reduce ovarian axis activity and, in ACTH-dependent forms, increase adrenal androgens. Menstrual irregularities, acne and hirsutism may occur, but these signs appear within a progressive systemic picture. Their isolated presence is insufficient to suspect hypercortisolism.
Fatigue, insomnia, anxiety and weight gain are common and poorly specific manifestations. Screening for Cushing’s syndrome becomes appropriate mainly when they occur together with more characteristic signs, such as proximal myopathy, spontaneous bruising, wide purple striae, facial plethora, early osteoporosis or hypertension that is difficult to control.
A single serum cortisol measurement does not measure the overall level of stress and does not diagnose Cushing’s syndrome. Time of day, sleep, illness, anxiety associated with blood collection, oral estrogens and numerous medications can alter the result. Tests must be selected and interpreted within the appropriate clinical context.
So-called “adrenal fatigue” is not a recognized endocrinological diagnosis. Validated tests should only be used in patients with an appropriate clinical suspicion. It has not been demonstrated that everyday stress progressively exhausts the adrenal gland’s ability to produce cortisol. Commercial cortisol profiles used to support this theory do not replace validated tests for genuine adrenal diseases.
True adrenal insufficiency is a different and potentially serious condition caused by damage to the adrenal cortex or ACTH deficiency. It can produce hypotension, weight loss, weakness, gastrointestinal symptoms and electrolyte abnormalities. Diagnosis requires appropriate measurements and, when indicated, dynamic testing.
Stress management strategies can nevertheless provide genuine benefits. Regularizing sleep, treating anxiety and depression, reducing alcohol consumption, improving recovery and adapting physical activity reduce the overall burden and can promote metabolic well-being. Their efficacy does not depend on a promise to “detoxify” cortisol, but on correcting the factors that maintain activation and unfavorable behaviors.
The functional history of the ovary begins before birth. The oocyte reserve reaches its maximum during fetal life and begins to decline before delivery; only a proportion remains at birth and puberty. During childhood, the hypothalamic-pituitary-ovarian axis is relatively quiescent, but follicles continue to be lost through atresia. With puberty, pulsatile GnRH secretion progressively resumes, LH and FSH increase and estrogen production, follicular maturation and ovulatory cyclicity become established.
Estradiol contributes to the development of secondary sexual characteristics, growth, skeletal maturation and adipose tissue distribution. Adolescence is a phase of high energy demand because linear growth, muscular development, skeletal mineralization and acquisition of reproductive function must occur simultaneously. Insufficient nutrition or excessive exercise can delay or interrupt this process.
The first cycles are often irregular because feedback mechanisms are not yet fully mature. Acne, menstrual variations and multifollicular ovaries may therefore be physiological during the first years after menarche. Distinguishing these findings from PCOS requires persistence of the abnormalities, evidence of hyperandrogenism and compliance with adolescent-specific criteria.
During adulthood, fluctuations in the ovarian cycle may temporarily influence temperature, fluid retention, appetite, sleep and perceived exertion. Their extent varies between women and between different cycles. These changes do not imply that metabolism is damaged or restored every month, but reflect physiological adaptation to changes in estradiol and progesterone.
Abnormalities become more clinically relevant when ovarian activity remains persistently altered, as in PCOS, hypothalamic amenorrhea or primary ovarian insufficiency. In these conditions, not only one hormone value changes: ovulation, fertility, estrogen exposure, androgen activity, insulin response, body composition and bone health may all be affected.
After fertilization, the corpus luteum supports the first weeks of pregnancy through progesterone and estradiol. The placenta then progressively assumes steroid production. During the second half of pregnancy, insulin resistance physiologically increases and the pancreas produces more insulin; estrogens, progesterone, transport proteins and cortisol rise. These changes are part of gestational physiology and should not be used as a model for nonpregnant women.
After childbirth, the abrupt decline in estrogens and progesterone, breastfeeding, fragmented sleep and increased energy requirements produce a new adaptation. Postpartum thyroiditis can superimpose thyrotoxic or hypothyroid symptoms on the fatigue and emotional changes typical of the period, making targeted assessment necessary when the clinical picture is severe or persistent.
The phase of greatest metabolic interest is the menopausal transition. The number of follicles declines and reduced inhibin B makes negative feedback on FSH less effective. FSH increases, but estradiol does not immediately decrease in a linear manner: it may fluctuate widely, being high in some cycles and low in others.
Progesterone also becomes less regular because ovulation occurs less predictably. This endocrine instability precedes definitive loss of follicular function and may last several years. Symptoms therefore do not depend on a simple constant deficiency, but on the combination of unpredictable fluctuations and progressive reduction in ovarian production.
Hot flushes result from a change in hypothalamic temperature regulation. Small variations are perceived as excessive and activate vasodilation and sweating. When episodes occur at night, repeated awakenings may cause fatigue, difficulty concentrating, irritability and reduced ability to recover from physical activity.
Fragmented sleep may in turn worsen insulin sensitivity, appetite and motivation to move. This creates a sequence in which ovarian change produces vasomotor symptoms, the symptoms disrupt sleep and sleep loss worsens metabolic well-being. Cortisol participates in adaptation, but does not necessarily represent the primary cause of the problem.
Menopause is retrospectively defined after twelve consecutive months of amenorrhea not explained by other causes. The physiology of the ovary during menopause is characterized by loss of follicular activity, a stable reduction in estradiol and progesterone and increased FSH and LH.
Ovarian androgen production declines more gradually. Peripheral tissues continue to convert adrenal and ovarian precursors into less potent estrogens, especially estrone. Adipose tissue participates in this conversion, but peripheral production does not restore normal estrogen exposure or prevent the skeletal and metabolic consequences of menopause.
Longitudinal studies show that the menopausal transition accelerates the increase in fat mass and the reduction in the proportion of lean mass. Overall weight may continue to increase at a rate not very different from previous years, while composition changes more rapidly. This explains why many women perceive a substantial bodily change without observing an equally marked increase on the scales.
Loss of muscle mass reduces strength, functional capacity and glucose uptake. At the same time, fat tends to be redistributed towards the abdomen and visceral compartment. The combination promotes insulin resistance, dyslipidemia and increased waist circumference even when food intake has not changed noticeably.
Midlife weight gain, however, is not caused exclusively by menopause. Aging progressively reduces muscle mass, spontaneous activity and energy expenditure; work, family responsibilities, sleep and available time for exercise may also change. Menopause mainly influences fat distribution and body composition, while energy balance continues to determine total mass.
This distinction is important because the change is neither inevitable nor completely reversible through a single hormonal treatment. Resistance training, aerobic activity, adequate protein intake and overall diet quality can limit muscle loss and improve insulin sensitivity and physical function.
The response varies between women. Family history of diabetes, previous PCOS, visceral adiposity, smoking, blood pressure, medications and activity level modify risk. A physically active woman may pass through menopause while maintaining good metabolic health; another with predisposition and comorbidities may experience more evident deterioration.
Reduced estrogen exposure also accelerates bone resorption. Loss is more rapid during the years surrounding the final menstrual period and adds to the effects of age, sedentary behavior and any nutritional deficiencies. Strength training and weight-bearing exercise protect bone, muscle and metabolism simultaneously.
When ovarian function declines before the age of 40, the condition is defined as primary ovarian insufficiency. The consequences involve reproductive function, bone, the cardiovascular system and psychological well-being. Hypoestrogenism begins many years before physiological menopause and increases exposure to bone loss, urogenital symptoms and cardiovascular risk. Hormone therapy in this context has a broader replacement function than the simple treatment of hot flushes. It does not, however, restore the follicular reserve or guarantee recovery of fertility; when pregnancy is desired, counseling must address intermittent ovulation, the possibility of spontaneous conception, fertility preservation when still feasible and medically assisted reproductive options.
The prevalence of thyroid dysfunction also increases with age. Fatigue, insomnia, increased abdominal circumference, muscle loss and mood changes may therefore result from the combined effects of menopause, aging, thyroid disease, medications and sleep disorders. The coexistence of several factors is often more plausible than a single cause capable of explaining everything.
Regular physical activity remains one of the main preventive tools. Aerobic exercise improves cardiorespiratory fitness and insulin sensitivity; resistance training preserves muscle mass and strength; everyday movement increases energy expenditure without necessarily requiring very intense sessions.
The intervention must, however, be proportionate to the woman’s condition. Indiscriminately increasing exercise in the presence of dietary restriction, amenorrhea and stress fractures may aggravate the energy deficit. The same recommendation therefore has opposite implications depending on whether the main problem is sedentary behavior or insufficient recovery.
Assessment should begin with the sequence in which symptoms appeared. Did weight gain precede or follow menstrual irregularity? Did hot flushes begin before insomnia? Does fatigue coincide with an increase in training, drug therapy or a change in working conditions? The chronology of symptoms makes it possible to construct a plausible relationship between symptoms and mechanisms.
The medical history includes menstrual pattern, age, contraception, hormone therapies, pregnancies, breastfeeding and symptoms of the menopausal transition. This information is not used solely to assess the reproductive system, but defines the context in which estrogens, FSH, progesterone and metabolic changes must be interpreted.
The pattern of weight and waist circumference must be reconstructed, distinguishing gradual variation from rapid change. Diet, restrictions, episodes of uncontrolled eating, physical activity, loss of strength and changes in body composition should be assessed. Current weight, when isolated from its history, provides incomplete information.
Sleep should be investigated systematically. Snoring, witnessed apneas, daytime sleepiness, shift work, nocturnal hot flushes and insomnia can influence energy and metabolism. Obstructive sleep apnea may be particularly relevant in women with PCOS, obesity or postmenopausal status and should not be confused with a generic cortisol disturbance.
The medication list should include oral, inhaled, topical, nasal or injected corticosteroids; levothyroxine; contraceptives; menopausal therapy; antipsychotics; antidepressants; opioids and supplements. Some medications promote weight gain or menstrual changes, while oral estrogens alter the proteins that transport thyroid hormones and cortisol.
Physical examination includes blood pressure, heart rate, weight, height and waist circumference. Assessment of fat distribution and muscle mass helps distinguish simple weight gain from a change in body composition. Skin, hair, acne, hirsutism, acanthosis nigricans, striae and bruising may point towards specific endocrine disorders.
Thyroid function is initially assessed using TSH and FT4. Elevated TSH with reduced FT4 indicates overt primary hypothyroidism; suppressed TSH with elevated FT4 or FT3 indicates thyrotoxicosis. Antibodies help define autoimmune etiology, but do not explain nonspecific symptoms when function remains normal.
In women of reproductive age with amenorrhea or menstrual irregularity, the first investigation is exclusion of pregnancy. Prolactin, TSH, FT4, FSH, LH and estradiol are selected according to the clinical picture. The objective is not to measure every available hormone, but to distinguish ovarian dysfunction from central suppression or a thyroid or pituitary cause.
When the question concerns fertility, assessment must determine whether ovulation occurs, but cannot stop at the ovary. Regular cycles lasting between 21 and 35 days are often ovulatory; in irregular cycles, menstrual history and, when necessary, luteal phase progesterone help document ovulation. Transvaginal ultrasound and antral follicle count describe morphology and reserve, while AMH and FSH provide information on follicular quantity or the response to stimulation, not a direct measure of oocyte quality.
Infertility assessment must simultaneously include ovulation, uterine anatomy, tubal patency and the male factor. Investigations are generally started after twelve months of regular unprotected intercourse in women younger than 35 years and after six months from the age of 35 onwards. Earlier assessment is appropriate after the age of 40 or in the presence of amenorrhea, markedly irregular cycles, endometriosis, previous pelvic surgery, chemotherapy, suspected tubal disease or known male factors.
Age remains the main nonmodifiable determinant of oocyte quality. Reduced AMH indicates a smaller quantity of recruitable follicles, but normal values do not eliminate the effect of age and low values do not mean that spontaneous conception is impossible. Similarly, a regular cycle does not exclude tubal disease, endometriosis, uterine abnormalities or a male factor. Reproductive function must be assessed as a property of the couple or reproductive plan, not as the simple sum of hormone measurements.
When hirsutism, persistent acne or irregular cycles are present, androgen assessment includes total testosterone measured using reliable methods, SHBG and estimation of the free fraction. DHEAS may indicate an adrenal contribution, while 17-hydroxyprogesterone is used in selected contexts to exclude nonclassic congenital adrenal hyperplasia.
Rapid onset of virilization, deepening of the voice or very high androgen concentrations requires prompt investigation. Ovarian or adrenal neoplasms and ovarian hyperthecosis must be excluded. Common PCOS generally produces a slower and less marked progression.
Diagnosis of PCOS in an adult requires at least two of the following: hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology, after excluding other causes. AMH can be used in adults as an alternative to ultrasound within an appropriate pathway, but does not constitute a general test of ovarian health. Ultrasound and AMH should not be used to establish the diagnosis in adolescents.
Metabolic assessment in PCOS includes blood pressure, a lipid profile and glucose metabolism. The oral glucose tolerance test is the most sensitive method for identifying impaired glucose tolerance and diabetes. Fasting blood glucose and HbA1c may be less sensitive in some women, particularly during the initial stages.
In women older than 45 years with typical symptoms and menstrual changes, perimenopause is diagnosed predominantly on clinical grounds. A single FSH result may be elevated or normal depending on timing and does not necessarily resolve the diagnostic question. Tests become more important in younger women or when manifestations are atypical.
Cortisol should not be measured indiscriminately for fatigue, stress, insomnia or weight gain. Investigation for Cushing’s syndrome is indicated when multiple and progressive features occur, such as proximal muscle weakness, easy bruising, wide purple striae, facial plethora, early osteoporosis or hypertension that is difficult to control.
Exposure to corticosteroids must be excluded before testing. In the presence of an appropriate suspicion, validated initial tests include 24-hour urinary free cortisol, late-night salivary cortisol and the dexamethasone suppression test. Random serum cortisol and isolated ACTH are not appropriate screening tests.
Commercial panels that measure numerous hormones without a clinical question increase the probability of finding values that are randomly outside the reference range. Variation may depend on time of day, cycle phase, medications or normal biological variability. An isolated result does not demonstrate that the measured hormone caused the symptom.
Treatment should be directed at the identified mechanism. Diet, physical activity, sleep and stress management are cross-cutting elements, but must be adapted to the situation. A woman with insulin resistance and sedentary behavior requires a different intervention from a woman with energy deficiency, excessive training and suppression of ovarian function.
An adequate diet must provide sufficient energy, protein, fiber, unsaturated fats and micronutrients. There is no single food capable of simultaneously rebalancing the ovary, thyroid and adrenal glands. Very restrictive diets may produce initial weight loss, but increase the risk of muscle loss, weight regain and menstrual abnormalities.
Resistance training is particularly important during midlife because it preserves muscle mass, strength, insulin sensitivity and bone. Aerobic exercise improves cardiorespiratory fitness and metabolic control. Volume should be progressive and sustainable, without turning movement into an additional factor contributing to energy deficiency and stress.
When pregnancy is the objective, treatment must be directed at the identified cause. Correction of thyroid dysfunction, hyperprolactinemia, energy deficiency and metabolic abnormalities may restore ovulation in selected conditions; ovulatory disorders may require medications for ovulation induction, while tubal, uterine or male disorders require specific interventions or medically assisted reproductive techniques. Treatment should not be selected solely on the basis of AMH or a generic hormonal panel.
Treatment of PCOS depends on the clinical objectives. Lifestyle interventions are recommended regardless of weight. Combined contraceptives can regulate bleeding and reduce androgen activity; metformin is mainly used for metabolic and glycemic components. Treatment should include prevention of diabetes and cardiovascular risk.
In functional hypothalamic amenorrhea, the priority is to correct the energy deficit by increasing intake, reducing exercise when excessive and restoring weight when necessary. Psychological support is useful when stress, perfectionism or eating disorders contribute to the condition. Inducing pharmacological bleeding without correcting the cause does not demonstrate recovery of the axis.
Overt hypothyroidism is treated with levothyroxine, adjusting the dose according to age, weight, pregnancy, comorbidities and TSH. Hyperthyroidism may require antithyroid drugs, radioiodine or surgery. Restoration of euthyroidism corrects effects genuinely attributable to the thyroid, but should not be used to justify excessive doses intended to promote weight loss.
During perimenopause, treatment is guided by symptom intensity, age and risk profile. Menopausal hormone therapy is the most effective treatment for hot flushes and night sweats and prevents bone loss during treatment. In women with a uterus, systemic estrogen must be combined with an adequate progestogen.
In healthy symptomatic women younger than 60 years or within ten years of menopause onset, the benefit-risk ratio is generally favorable in the absence of contraindications. The choice between oral and transdermal estrogens takes thromboembolic risk, metabolism, thyroid therapy, preferences and individual needs into account.
Hormone therapy should not be prescribed solely for the purpose of inducing weight loss. It may exert favorable effects on fat distribution and insulin sensitivity in some women, but does not replace diet, physical activity and treatment of other metabolic conditions. Its primary objective remains symptom control and, when indicated, bone protection.
Sleep disorders should be treated specifically. Control of hot flushes may improve awakenings; suspected apnea requires a dedicated diagnostic pathway; insomnia, anxiety and depression may benefit from appropriate psychological and pharmacological interventions. Reducing the problem to cortisol risks delaying effective treatment.
Cushing’s syndrome requires treatment of the cause of hypercortisolism through surgery, medications, radiotherapy or other specialist strategies. No diet, relaxation technique or supplement can correct autonomous cortisol production. Diabetes, hypertension, osteoporosis and thromboembolic risk must be treated simultaneously.
Hormonal supplements marketed for the “thyroid”, “adrenal glands” or “hormonal balance” are not automatically harmless. They may contain high amounts of iodine, glandular extracts, thyroid hormones or pharmacologically active substances. They may also interfere with tests and make it more difficult to identify the actual mechanism responsible for symptoms.
Prognosis depends on the cause, but most conditions can be effectively managed. PCOS requires ongoing metabolic monitoring; thyroid dysfunction improves with restoration of euthyroidism; hypothalamic amenorrhea may resolve when energy availability is corrected; menopausal symptoms can be treated using individualized hormonal or nonhormonal strategies.
The common principle is to distinguish normal endocrine fluctuations from documentable disease. The ovary, thyroid and cortisol genuinely interact in the regulation of energy, body composition and well-being, but no single hormone explains every symptom by itself. The most effective assessment reconstructs the physiological connections and intervenes on the factor that has actually altered them.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.